<DOC>
	<DOCNO>NCT01285609</DOCNO>
	<brief_summary>The purpose study determine whether Ipilimumab plus Paclitaxel Carboplatin extend live patient squamous non small cell lung cancer placebo plus Paclitaxel Carboplatin .</brief_summary>
	<brief_title>Phase 3 Trial Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo Addition Paclitaxel Carboplatin</brief_title>
	<detailed_description>The primary objective compare Overall Survival ( OS ) participant Stage IV/recurrent NSCLC squamous histology randomize ipilimumab addition paclitaxel carboplatin versus placebo addition paclitaxel carboplatin , receive least one dose blind study therapy ( ipilimumab placebo ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Non small cell lung cancer ( NSCLC ) squamous cell Stage IV recurrent NSCLC Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Brain Metastases Autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>